Valneva SE (INRLF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Valneva SE (INRLF) with AI Score 57/100 (Hold). Valneva SE is a specialty vaccine company focused on developing and commercializing vaccines for infectious diseases with unmet needs. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Valneva SE (INRLF) Healthcare & Pipeline Overview
Valneva SE is a specialty vaccine company focused on developing and commercializing prophylactic vaccines against infectious diseases with unmet needs, including Japanese encephalitis and chikungunya. With a global presence and a diverse pipeline of vaccine candidates, Valneva aims to address significant public health challenges and expand its market reach in the biotechnology sector.
Investment Thesis
Valneva SE presents a notable research candidate within the biotechnology sector, driven by its established vaccine portfolio and promising pipeline of vaccine candidates. The company's existing commercialized vaccines, including IXIARO and DUKORAL, generate revenue and provide a foundation for future growth. The recent approval of IXCHIQ/VLA1553 for chikungunya represents a significant milestone and a potential revenue stream. Valneva's Lyme disease vaccine candidate, VLA15, is a key value driver, addressing a substantial unmet need in a growing market. The company's negative P/E ratio of -7.22 reflects its investment in R&D and clinical trials, which could yield substantial returns upon successful product launches. However, potential risks include clinical trial setbacks, regulatory hurdles, and competition from established pharmaceutical companies.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.88 billion reflects investor valuation of Valneva's current and future potential.
- Gross margin of 45.4% indicates efficient vaccine production and pricing strategies.
- Negative profit margin of -56.8% reflects ongoing investments in research and development for future growth.
- Beta of 1.27 suggests higher volatility compared to the overall market, typical for biotechnology companies.
- Valneva's diverse vaccine pipeline targets multiple infectious diseases, reducing reliance on a single product.
Competitors & Peers
Strengths
- Diverse portfolio of commercialized vaccines and vaccine candidates.
- Specialized expertise in vaccine development and manufacturing.
- Established distribution networks in key markets.
- Proprietary vaccine technologies and intellectual property.
Weaknesses
- Negative profit margin due to high R&D expenses.
- Reliance on regulatory approvals for new vaccine launches.
- Competition from established pharmaceutical companies.
- Limited financial resources compared to larger competitors.
Catalysts
- Upcoming: Clinical trial results for VLA15 (Lyme disease vaccine candidate) expected in late 2026.
- Ongoing: Commercialization and distribution of IXCHIQ/VLA1553 for chikungunya.
- Ongoing: Expansion of existing vaccine sales in key geographic markets.
- Upcoming: Regulatory approvals for new vaccine candidates in the pipeline.
- Ongoing: Strategic partnerships and collaborations to accelerate vaccine development.
Risks
- Potential: Clinical trial failures and regulatory setbacks.
- Potential: Competition from established pharmaceutical companies.
- Potential: Changes in government regulations and reimbursement policies.
- Ongoing: Negative profit margin due to high R&D expenses.
- Potential: Product liability claims and litigation.
Growth Opportunities
- Expansion of IXCHIQ/VLA1553 for Chikungunya: Valneva's IXCHIQ vaccine, targeting the chikungunya virus, represents a significant growth opportunity. With a market size estimated to reach hundreds of millions of dollars, the vaccine addresses a critical unmet need, especially in regions where the virus is endemic. The single-dose nature of the vaccine offers a competitive advantage, simplifying administration and improving patient compliance. Successful commercialization and distribution of IXCHIQ could drive substantial revenue growth for Valneva.
- Advancement of Lyme Disease Vaccine Candidate (VLA15): Valneva's VLA15 vaccine candidate against Lyme disease is a key growth driver, targeting a market with increasing prevalence and limited treatment options. The vaccine has the potential to generate significant revenue upon approval, addressing a substantial unmet need. Positive clinical trial results and regulatory approvals would be major catalysts for Valneva's growth in the coming years.
- Development of Vaccine Candidates for Emerging Infectious Diseases: Valneva's pipeline includes vaccine candidates targeting emerging infectious diseases such as Zika virus, human metapneumovirus, Clostridium difficile, and Epstein-Barr virus. These programs represent long-term growth opportunities, positioning the company to address future public health threats. Successful development and commercialization of these vaccines could drive substantial revenue growth and enhance Valneva's reputation as an innovator in the vaccine space.
- Geographic Expansion into New Markets: Valneva has the opportunity to expand its geographic presence into new markets, particularly in Asia and Latin America, where the prevalence of infectious diseases is high. By establishing partnerships and distribution networks in these regions, Valneva can increase its market reach and drive revenue growth. This expansion strategy aligns with the company's mission to address global health challenges and improve access to vaccines worldwide.
- Strategic Partnerships and Collaborations: Valneva can leverage strategic partnerships and collaborations to accelerate the development and commercialization of its vaccine candidates. Collaborating with other pharmaceutical companies, research institutions, and government agencies can provide access to funding, expertise, and resources, enhancing Valneva's capabilities and reducing its financial risk. These partnerships can also facilitate the expansion of Valneva's product portfolio and market reach.
Opportunities
- Expansion into new geographic markets.
- Development of vaccine candidates for emerging infectious diseases.
- Strategic partnerships and collaborations.
- Increasing demand for vaccines due to global health concerns.
Threats
- Clinical trial failures and regulatory setbacks.
- Competition from biosimilars and generic vaccines.
- Changes in government regulations and reimbursement policies.
- Economic downturns and reduced healthcare spending.
Competitive Advantages
- Specialized expertise in vaccine development and manufacturing.
- Proprietary vaccine technologies and intellectual property.
- Established distribution networks and partnerships.
- Regulatory approvals and market exclusivity for commercialized vaccines.
About INRLF
Valneva SE, founded in 1998 and headquartered in Saint-Herblain, France, is a specialty vaccine company dedicated to developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. The company's mission is to leverage its expertise in vaccine development to address global health challenges and improve the lives of people worldwide. Valneva's commercialized product portfolio includes IXIARO, a vaccine against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholerae; and IXCHIQ/VLA1553, a single-dose vaccine for chikungunya. In addition to its commercial products, Valneva has a robust pipeline of vaccine candidates targeting diseases such as Lyme disease (VLA15), shigellosis (S4V2), Zika virus (VLA1601), human metapneumovirus (VLA1554), Clostridium difficile infection (VLA84), and Epstein-Barr virus (VLA2112). Valneva distributes its vaccines across the United States, Canada, Germany, Austria, the Nordics, the United Kingdom, France, the rest of Europe, and other international markets.
What They Do
- Develops and commercializes prophylactic vaccines for infectious diseases.
- Offers IXIARO, a vaccine against Japanese encephalitis.
- Provides DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera.
- Markets IXCHIQ/VLA1553, a single-dose vaccine for chikungunya.
- Develops VLA15, a vaccine candidate against Lyme disease.
- Creates vaccine candidates for Zika virus, human metapneumovirus, and other infectious diseases.
- Sells its products in the United States, Canada, Europe, and internationally.
Business Model
- Develops and manufactures vaccines for infectious diseases.
- Generates revenue through the sale of commercialized vaccines.
- Out-licenses vaccine technologies and forms strategic partnerships.
- Receives funding through government grants and research collaborations.
Industry Context
Valneva operates within the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. The global vaccine market is projected to reach billions of dollars by 2026, driven by increasing awareness of infectious diseases and government initiatives to promote vaccination. Valneva competes with established pharmaceutical companies and other biotechnology firms in the development and commercialization of vaccines. The company's focus on specialty vaccines for unmet needs differentiates it from competitors and positions it for growth in niche markets.
Key Customers
- Travelers visiting regions where Japanese encephalitis, cholera, or chikungunya are prevalent.
- Military personnel deployed to areas with high risk of infectious diseases.
- Individuals living in or traveling to areas endemic for Lyme disease.
- Government agencies and public health organizations.
Financials
Chart & Info
Valneva SE (INRLF) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INRLF.
Price Targets
Wall Street price target analysis for INRLF.
MoonshotScore
What does this score mean?
The MoonshotScore rates INRLF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
INRLF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Valneva SE (INRLF) may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges due to the lack of stringent listing requirements.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Higher price volatility due to lower trading volumes.
- Potential for wider bid-ask spreads.
- Increased risk of fraud or manipulation.
- Limited regulatory oversight compared to major exchanges.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Monitor news and press releases for any updates or developments.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Established presence in the vaccine industry.
- Commercialized products and a pipeline of vaccine candidates.
- Partnerships with reputable organizations.
- Scientific publications and presentations.
- Experienced management team.
What Investors Ask About Valneva SE (INRLF)
What does Valneva SE do?
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. The company's product portfolio includes vaccines for Japanese encephalitis (IXIARO), cholera (DUKORAL), and chikungunya (IXCHIQ/VLA1553). Valneva also has a pipeline of vaccine candidates targeting diseases such as Lyme disease, Zika virus, human metapneumovirus, Clostridium difficile, and Epstein-Barr virus. The company sells its products in the United States, Canada, Europe, and internationally, focusing on markets where these infectious diseases pose a significant public health threat.
What do analysts say about INRLF stock?
AI analysis is pending for INRLF. Generally, biotechnology stocks are evaluated based on their pipeline progress, clinical trial results, and potential market size for their products. Investors should monitor analyst ratings and price targets, but also conduct their own due diligence to assess the company's prospects and risks. Key valuation metrics include revenue growth, R&D spending, and potential earnings from future product launches. The stock's volatility should also be considered, as biotechnology stocks can be sensitive to news and regulatory developments.
What are the main risks for INRLF?
Valneva faces several risks inherent in the biotechnology industry. Clinical trial failures and regulatory setbacks are significant concerns, as delays or rejections can impact the company's pipeline and future revenue. Competition from established pharmaceutical companies with greater resources and market presence poses a challenge. Changes in government regulations and reimbursement policies can also affect the profitability of Valneva's products. Additionally, the company's negative profit margin due to high R&D expenses requires careful monitoring, as it relies on successful product launches to achieve profitability.
What are the key factors to evaluate for INRLF?
Valneva SE (INRLF) currently holds an AI score of 57/100, indicating moderate score. Key strength: Diverse portfolio of commercialized vaccines and vaccine candidates.. Primary risk to monitor: Potential: Clinical trial failures and regulatory setbacks.. This is not financial advice.
How frequently does INRLF data refresh on this page?
INRLF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven INRLF's recent stock price performance?
Recent price movement in Valneva SE (INRLF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse portfolio of commercialized vaccines and vaccine candidates.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider INRLF overvalued or undervalued right now?
Determining whether Valneva SE (INRLF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying INRLF?
Before investing in Valneva SE (INRLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending for INRLF and may provide additional insights.